#BEGIN_DRUGCARD DB01909

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
10016-20-3

# ChEBI_ID:
33103

# Chemical_Formula:
C36H60O30

# Chemical_IUPAC_Name:
(1S,3S,5R,6S,8S,10S,11S,13S,15S,16S,18S,20S,21S,23S,25S,26S,28S,30S,31R,32R,33R,34R,35R,36R,37R,38R,39R,40R,41R,42R)-5,10,15,20,25,30-hexakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29-dodecaoxaheptacyclo[26.2.2.2^{3,6}.2^{8,11}.2^{13,16}.2^{18,21}.2^{23,26}]dotetracontane-31,32,33,34,35,36,37,38,39,40,41,42-dodecol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Alpha-Cyclodextrin (Cyclohexa-Amylose)

# HET_ID:
ACX

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C36H60O30/c37-1-7-25-13(43)19(49)31(55-7)62-26-8(2-38)57-33(21(51)15(26)45)64-28-10(4-40)59-35(23(53)17(28)47)66-30-12(6-42)60-36(24(54)18(30)48)65-29-11(5-41)58-34(22(52)16(29)46)63-27-9(3-39)56-32(61-25)20(50)14(27)44/h7-54H,1-6H2/t7-,8-,9-,10-,11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31-,32-,33-,34-,35-,36-/m0/s1

# InChI_Key:
InChIKey=HFHDHCJBZVLPGP-KREQUGERSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1909

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
972.8436

# Molecular_Weight_Mono:
972.31694058

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1CXF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.4

# Predicted_LogS:
-0.09

# Predicted_Water_Solubility:
7.92e+02 g/l

# Primary_Accession_No:
DB01909

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936256

# PubChem_Substance_ID:
46507190

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00422

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@H]1O[C@H]2O[C@@H]3[C@H](CO)O[C@@H](O[C@@H]4[C@H](CO)O[C@@H](O[C@@H]5[C@H](CO)O[C@@H](O[C@@H]6[C@H](CO)O[C@@H](O[C@@H]7[C@H](CO)O[C@@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:36 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X78145

# Drug_Target_1_GenBank_ID_Protein:
510492

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cgt

# Drug_Target_1_Gene_Sequence:
>2142 bp
ATGAAGAAATTTCTGAAATCGACAGCTGCGCTTGCCCTGGGATTATCGCTGACGTTCGGG
CTTTTCAGCCCTGCCCAGGCCGCGCCGGATACCTCGGTATCCAACAAGCAAAATTTCAGC
ACCGACGTCATCTATCAAATTTTCACCGACAGGTTTTCGGACGGCAATCCCGCCAACAAT
CCGACCGGCGCGGCGTTTGACGGAACCTGCACGAACCTCCGGCTGTATTGCGGCGGCGAC
TGGCAGGGCATCATCAACAAAATCAACGACGGTTACCTGACCGGGATGGGCGTTACCGCC
ATCTGGATCTCCCAGCCGGTCGAAAACATCTACAGCATCATCAATTATTCCGGCGTAAAC
AACACGGCCTATCACGGCTACTGGGCCCGGGACTTCAAGAAGACGAATCCGGCCTACGGC
ACGATTGCGGACTTCCAGAACCTGATCGCCGCCGCGCATGCAAAAAACATCAAAGTCATT
ATCGACTTTGCCCCGAACCATACGTCGCCCGCCTCGTCCGACCAGCCTTCCTTTGCGGAA
AACGGCCGGCTGTACGATAACGGCACGCTGCTCGGGGGATACACGAACGATACGCAGAAC
CTGTTCCACCATAACGGCGGCACGGACTTTTCCACGACCGAAAACGGCATCTACAAAAAC
CTGTACGATCTCGCCGACCTGAACCATAACAACAGCACCGTGGACGTCTACTTGAAGGAC
GCGATCAAAATGTGGCTGGACCTCGGCATCGACGGCATCCGCATGGATGCGGTGAAGCAT
ATGCCGTTCGGCTGGCAGAAGAGCTTTATGGCTGCCGTCAACAACTATAAGCCGGTCTTT
ACCTTCGGCGAATGGTTCCTGGGCGTAAATGAAGTGAGCCCGGAAAACCATAAGTTTGCC
AACGAATCCGGCATGAGCCTGCTTGATTTCCGTTTTGCCCAAAAGGTGCGGCAGGTGTTC
CGGGACAACACCGACAATATGTACGGCCTGAAGGCGATGCTGGAGGGCTCCGCAGCCGAT
TACGCCCAGGTGGATGACCAGGTGACGTTCATCGACAACCATGACATGGAGCGTTTCCAC
GCAAGCAATGCAAACCGCCGGAAGCTGGAGCAAGCGCTTGCGTTCACGCTGACCTCGCGC
GGCGTCCCCGCCATTTATTACGGCACCGAGCAGTACATGTCGGGCGGGACCGATCCGGAC
AACCGGGCGCGGATCCCTTCCTTCTCCACGTCGACGACCGCCTATCAGGTCATTCAAAAG
CTGGCGCCGCTGCGCAAGTGCAACCCGGCCATCGCCTACGGATCGACGCAGGAGCGCTGG
ATCAACAACGACGTGCTCATTTATGAGCGCAAATTCGGCAGCAACGTTGCCGTCGTTGCC
GTCAACCGCAATTTAAACGCGCCGGCTTCCATTTCGGGACTTGTCACTTCCCTGCCGCAA
GGCAGCTACAACGACGTCCTTGGCGGCCTTCTGAACGGCAACACGTTATCGGTAGGCTCC
GGCGGGGCCGCCTCCAATTTCACGCTTGCGGCCGGCGGCACGGCGGTGTGGCAGTACACC
GCGGCTACGGCGACGCCGACCATCGGGCATGTCGGGCCGATGATGGCCAAGCCGGGCGTG
ACGATCACGATCGACGGCCGCGGCTTCGGCTCTAGCAAAGGCACCGTCTACTTCGGTACG
ACGGCGGTGAGCGGGGCGGACATCACGTCTTGGGAAGACACGCAGATCAAAGTGAAAATT
CCGGCCGTCGCAGGCGGCAACTACAACATTAAAGTCGCAAACGCTGCCGGAACGGCAAGC
AATGTGTATGACAACTTCGAGGTATTGTCCGGAGACCAGGTCAGCGTCCGCTTCGTGGTC
AACAACGCGACGACGGCCCTTGGGCAAAATGTGTACCTGACGGGCAGTGTCAGCGAGCTG
GGGAACTGGGACCCGGCAAAAGCAATCGGGCCGATGTACAATCAGGTCGTTTACCAATAT
CCGAACTGGTATTATGACGTCAGCGTTCCGGCCGGCAAAACGATCGAGTTCAAGTTTTTG
AAAAAACAAGGCTCCACCGTCACGTGGGAAGGCGGCAGCAACCACACCTTCACCGCGCCG
TCCAGCGGCACCGCGACCATTAACGTGAATTGGCAGCCATAA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
7493956	Knegtel RM, Strokopytov B, Penninga D, Faber OG, Rozeboom HJ, Kalk KH, Dijkhuizen L, Dijkstra BW: Crystallographic studies of the interaction of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 with natural substrates and products. J Biol Chem. 1995 Dec 8;270(49):29256-64.
8107143	Lawson CL, van Montfort R, Strokopytov B, Rozeboom HJ, Kalk KH, de Vries GE, Penninga D, Dijkhuizen L, Dijkstra BW: Nucleotide sequence and X-ray structure of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 in a maltose-dependent crystal form. J Mol Biol. 1994 Feb 18;236(2):590-600.
8672460	Strokopytov B, Knegtel RM, Penninga D, Rozeboom HJ, Kalk KH, Dijkhuizen L, Dijkstra BW: Structure of cyclodextrin glycosyltransferase complexed with a maltononaose inhibitor at 2.6 angstrom resolution. Implications for product specificity. Biochemistry. 1996 Apr 2;35(13):4241-9.
8955113	Penninga D, van der Veen BA, Knegtel RM, van Hijum SA, Rozeboom HJ, Kalk KH, Dijkstra BW, Dijkhuizen L: The raw starch binding domain of cyclodextrin glycosyltransferase from Bacillus circulans strain 251. J Biol Chem. 1996 Dec 20;271(51):32777-84.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2523

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
77310

# Drug_Target_1_Name:
Cyclomaltodextrin glucanotransferase

# Drug_Target_1_Number_of_Residues:
713

# Drug_Target_1_PDB_ID:
2CXG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF00686	CBM_20
PF01833	TIG
PF02806	Alpha-amylase_C

# Drug_Target_1_Protein_Sequence:
>Cyclomaltodextrin glucanotransferase precursor
MKKFLKSTAALALGLSLTFGLFSPAQAAPDTSVSNKQNFSTDVIYQIFTDRFSDGNPANN
PTGAAFDGTCTNLRLYCGGDWQGIINKINDGYLTGMGVTAIWISQPVENIYSIINYSGVN
NTAYHGYWARDFKKTNPAYGTIADFQNLIAAAHAKNIKVIIDFAPNHTSPASSDQPSFAE
NGRLYDNGTLLGGYTNDTQNLFHHNGGTDFSTTENGIYKNLYDLADLNHNNSTVDVYLKD
AIKMWLDLGIDGIRMDAVKHMPFGWQKSFMAAVNNYKPVFTFGEWFLGVNEVSPENHKFA
NESGMSLLDFRFAQKVRQVFRDNTDNMYGLKAMLEGSAADYAQVDDQVTFIDNHDMERFH
ASNANRRKLEQALAFTLTSRGVPAIYYGTEQYMSGGTDPDNRARIPSFSTSTTAYQVIQK
LAPLRKCNPAIAYGSTQERWINNDVLIYERKFGSNVAVVAVNRNLNAPASISGLVTSLPQ
GSYNDVLGGLLNGNTLSVGSGGAASNFTLAAGGTAVWQYTAATATPTIGHVGPMMAKPGV
TITIDGRGFGSSKGTVYFGTTAVSGADITSWEDTQIKVKIPAVAGGNYNIKVANAAGTAS
NVYDNFEVLSGDQVSVRFVVNNATTALGQNVYLTGSVSELGNWDPAKAIGPMYNQVVYQY
PNWYYDVSVPAGKTIEFKFLKKQGSTVTWEGGSNHTFTAPSSGTATINVNWQP

# Drug_Target_1_Reaction:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_SwissProt_ID:
P43379

# Drug_Target_1_SwissProt_Name:
CDGT2_BACCI

# Drug_Target_1_Synonyms:
CGTase
Cyclodextrin-glycosyltransferase
Cyclomaltodextrin glucanotransferase precursor
EC 2.4.1.19

# Drug_Target_1_Theoretical_pI:
6.52

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01909
